AstraZeneca Pharma India Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AstraZeneca Pharma India Limited generated cash of $278,700,000, which is less than the previous year. Cash used in financing activities reached the amount of -$443,800,000 last year. Net change in cash is therefore $52,300,000.
Cash Flow
| 2011 | 645.01M | -276.85M | -290.92M |
|---|---|---|---|
| 2012 | 377.26M | -326.82M | -290.71M |
| 2016 | 569.88M | -36.05M | -5.14M |
| 2018 | 87.9M | -93.6M | 0 |
| 2020 | 874.2M | -1.70B | -63.6M |
| 2021 | 1.04B | 1.73B | -89.7M |
| 2023 | 582.98M | 181.06M | -244.84M |
| 2024 | 278.7M | 217.4M | -443.8M |
ASTRAZEN.NS Cash Flow Statement (2011 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.00B | 4.48B | 835M | 1.73B | 1.14B | 233.32M | 728.41M | 651.19M |
Operating activities | ||||||||
Net income | 1.61B | 1.34B | 1.27B | 1.13B | 438M | 57.63M | 197.65M | 641.29M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 149.4M | 162.6M | 197.5M | 185.8M | 147.4M | 174.26M | 73.38M | 88.12M |
Stock-based compensation expense | 27.4M | 23.71M | 14.8M | 11.2M | 8.6M | 4.08M | 0 | 0 |
| Deferred income tax benefit | 27.4M | 23.71M | 14.8M | 11.2M | 8.6M | 4.08M | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -506.23M | -236.3M | -45.7M | -58.6M | -116M | -406.08M | 0 | 0 |
Inventories | -376.67M | -499.94M | 53.5M | -470.3M | -554.4M | 94.01M | -178.94M | -220.02M |
Accounts payable | -313.66M | 374.4M | -313.4M | 414.5M | 76.9M | 0 | 0 | 0 |
Cash generated by operating activities | 278.7M | 582.98M | 1.04B | 874.2M | 87.9M | 569.88M | 377.26M | 645.01M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | -1.71B | -1.69B | -110.8M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -107.6M | -85.2M | -77.1M | -142.2M | -62.8M | -90.44M | -398.42M | -322.74M |
Acquisitions Net | 0 | 34.8M | 24.2M | 4.9M | 300K | 1.26M | 0 | 0 |
Cash generated by investing activities | 217.4M | 181.06M | 1.73B | -1.70B | -93.6M | -36.05M | -326.82M | -276.85M |
Financing activities | ||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | -400M | -200M | -50M | -30.1M | 0 | 0 | -249.60M | -249.31M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -28.8M | 0 | 0 | -2.75M | 0 | 0 |
Cash used in financing activities | -443.8M | -244.84M | -89.7M | -63.6M | 0 | -5.14M | -290.71M | -290.92M |
Net Change In Cash | 52.3M | 519.20M | 2.68B | -897.4M | -5.7M | 528.68M | -240.27M | 77.22M |
Cash at end of period | 5.05B | 5.00B | 3.52B | 835M | 1.13B | 762.00M | 488.14M | 728.41M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |